RA, Jeito and Omega back a small Swiss biotech to en­ter an I/O field paved by Adap­ti­m­mune

A li­cens­ing deal worth up to $520 mil­lion has been fu­el­ing lit­tle-known Swiss biotech CDR-Life since May 2020, but the five-year-old start­up is ready to haul in tra­di­tion­al ven­ture cap­i­tal fi­nanc­ing.

Af­ter Boe­hinger In­gel­heim ful­ly took con­trol of the duo’s col­lab­o­ra­tion on a pre­clin­i­cal an­ti­body for ge­o­graph­ic at­ro­phy — one of the lead­ing caus­es of blind­ness — last sum­mer, CDR-Life went to work find­ing in­vestors to take its plat­form for­ward in sol­id tu­mors. Fill­ing that fund­ing role are RA Cap­i­tal Man­age­ment and Rafaèle Tord­j­man’s Jeito Cap­i­tal, who are co-lead­ing CDR-Life’s $76 mil­lion Se­ries A with help from Otel­lo Stam­pac­chia’s Omega Funds.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN